KALA BIO, Inc. KALA

KALA Company Overview

KALA BIO, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare and severe ophthalmic diseases. The company has historically operated in the eye care and biotechnology industries, with a concentration on treatments targeting diseases of the cornea and retina. KALA BIO became known for its proprietary mucus-penetrating particle drug delivery platform, which was used in earlier commercial ophthalmology products, and later repositioned its strategy toward biologic and regenerative medicine programs for underserved ophthalmic indications.

The company’s primary business focus has evolved from commercial ophthalmic therapeutics toward clinical development programs, particularly involving regenerative biologic candidates for ocular surface disease and retinal disorders. KALA BIO’s strategic positioning has centered on addressing conditions with limited approved therapies and high unmet medical need. The company originated from academic and drug delivery research associated with advances in particle-based ocular therapeutics and subsequently transitioned into a publicly traded biotechnology company pursuing specialty ophthalmology assets.